Celldex cancer drug candidate returns positive news

By Mass High Tech staff

Video Gallery

MHT's Julie Donnelly: Life science startups finding investments

MHT's Marc Songini: Technology to keep seniors healthy

MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban

OncoPep licenses cancer vaccine, moves to add $500K to Series A [February 13, 2012]

VBI Vaccines pulls in $2.2M debt round [February 13, 2012]

Zalicus, Hydra team up on pain treatment [February 10, 2012]

Ironwood stock offering aims for $80M [February 10, 2012]

Needham biotech Celldex Therapeutics Inc. received positive results from Phase 1 studies of its drug candidate, CDX-1307, intended to treat a number of cancers.

CDX-1307 is designed for vaccine delivery using monoclonal antibodies against the cancer target, hCG beta. The Phase 1 study, which was intended to test the safety and immunogenicity of CDX-1307, returned positive results for the drug candidate’s immunological and biological responses.

Celldex (Nasdaq: CLDX) tested 80 patients diagnosed and pretreated for breast, colon, bladder and pancreatic cancer. The results returned positive safety information and no limitations on dosage.

CDX-1307 is the first drug candidate from Celldex’s Precision Targeted Immunotherapy Platform.

Celldex was founded as Avant Immunotherapeutics Inc., and merged with New Jersey-based Celldex in early 2008 in a $128 million stock deal. Avant changed its name to Celldex in September of 2008, but retained its headquarters in Needham and its manufacturing plant in Fall River.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.